The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.

Like Comment
We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated-phase chronic myeloid leukemia (CML-AP) at diagnosis. Patients had at least 1 feature of AP: blasts ≥ 15% (n = 2), basophils ≥ 20% (n = 19), platelets


Click here to read the full article @ American journal of hematology

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2841 Contributions
1 Followers
0 Following

No comments yet.